Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has leveraged the flexibility of its clinically-validated NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes.
Revenues and growth are driven from out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide. In addition, the Company is seeking to monetize its existing product pipeline, including its first product, Vitaros®, approved in Canada for the treatment of erectile dysfunction, which is currently expected to be available on the Canadian market by the second half of 2011 and compounds in development from pre-clinical through Phase III, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others.
For further information on Apricus Bio, visit www.apricusbio.com and for information on its subsidiaries please visit www.nexmedusa.com.
In this video, Dr. Hachicha talks with Ed Cox about how NexACT® (DDAIP) helps deliver drugs through the processes of going through the cell membrane.
Richard Pascoe , Chief Executive Officer
Mr. Pascoe joined Apricus Bio in March of 2013 following the merger of Somaxon Pharmaceuticals with Pernix. At Somaxon Mr. Pascoe was the Chief Executive Officer since August 2008 and was responsible for the FDA approval of Somaxon’s lead drug Silenor®. Prior to Somaxon, Mr. Pascoe was with ARIAD Pharmaceuticals, Inc., a specialty pharmaceutical company where he was most recently Senior Vice President and Chief Operating Officer.
Prior to joining ARIAD in 2005, Mr. Pascoe held a series of senior management roles at King Pharmaceuticals, Inc., a specialty pharmaceutical company, including Senior Vice President positions in both marketing and sales, as well as Vice President positions in both international sales and marketing and hospital sales. Prior to King, Mr. Pascoe was in the commercial groups at Medco Research, Inc. (which was acquired by King), COR Therapeutics, Inc., B. Braun Interventional and The BOC Group.
Mr. Pascoe served as a Commissioned Officer with the U.S. Army 24th Infantry Division, following his graduation from the United States Military Academy at West Point where he received a B.S degree in Leadership.
Steve Martin, Senior Vice President, Chief Financial Officer
Mr. Martin, a certified public accountant, has over 25 years of financial leadership, with significant expertise in growing public companies in a variety of industries, including the life sciences. Since 2008, Mr. Martin served as Senior Vice President and Chief Financial Officer of BakBone Software, a publicly-traded software company. Mr. Martin also served as Interim CEO over the final 10 months with BakBone and through the successful sale of the company that was completed in January of 2011. From 2005 to 2007, Mr. Martin served as Chief Financial Officer of Stratagene Corporation, a publicly-traded company specializing in the development, manufacture and marketing of specialized research and clinical diagnostic products. Mr. Martin's experience also includes the position of Controller with publicly-traded Gen-Probe Incorporated, a life sciences company, as well as 10 years with the public accounting firm of Deloitte & Touche.
Mr. Martin holds a B.S. in Accounting from San Diego State University. In 2011, Mr. Martin was awarded the San Diego Business Journal's "CFO of the Year Award" for Medium Public Companies. He is also the former President and a member of the Board of Directors of the Financial Executives International San Diego Chapter.
Richard Martin, Ph.D., Vice President of Chemistry
Dr. Martin has over 20 years of research and development experience in the fields of antibacterial, inflammation, oncology, antiviral, antifungal, cardiovascular and metabolic diseases as well as sexual dysfunction. Dr. Martin oversees the chemistry, manufacturing and supply chain activities for the company, which he joined as Vice President of Chemistry in March 2010. Previously, Dr. Martin was the Senior Director of Chemistry, founding partner and investor of RetroVirox. Dr. Martin was also with X-Ceptor therapeutics as the Director of Chemistry, which was acquired by Exelixis in 2004 for their valuable metabolic disease programs.
Dr. Martin obtained his Ph.D. from the University of Toronto and pursued postdoctoral studies at The Scripps Research Institute in San Diego. He has over 30 patent applications, 13 of which have been granted in the United States and several publications in peer-reviewed journals.